Journals / Sağlık Akademisyenleri Dergisi / 2020 / Cilt: 7 - Sayı: 4

Fecal microbiota transplantation and its effects on diseases

Fekal mikrobiyota transplantasyonu ve hastalıklar üzerine etkileri

Pages
296–303
Publication Date
2020-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But the lack of long-term follow-up after implementation has led to criticism of FMT, and more work is needed on the reliability of the application.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The human body has a large number of microorganisms called microbiota.
📊
Key Findings & Data:Along with these microorganisms affecting various systems, the most focused area is the gastrointestinal tract.
💡
Conclusion & Impact:But the lack of long-term follow-up after implementation has led to criticism of FMT, and more work is needed on the reliability of the application.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:fekal mikrobiyota transplantasyonu · mikrobiyom · mikrobiyota

Abstract

The human body has a large number of microorganisms called microbiota. Along with these microorganisms affecting various systems, the most focused area is the gastrointestinal tract. The first studies on microbiota were conducted to develop treatment against Clostridium difficile infection. Today, it has been determined that it affects many mechanisms outside the gastrointestinal tract with better recognition of the microbiota. It has been determined that the negatives in the microbiota cause various diseases, and new treatment stategies are being developed. These include recent Fecal Microbiota Transplantation (FMT). FMT is popularly implemented and promising in several countries. But the lack of long-term follow-up after implementation has led to criticism of FMT, and more work is needed on the reliability of the application.

Özet

İnsan vücudunda mikrobiyota adı verilen çok sayıda mikroorganizma bulunmaktadır. Bu mikroorganizmalar çeşitli sistemleri etkilemek ile beraber en çok üzerinde durulan alan gastrointestinal sistemdir. Mikrobiyota üzerine ilk çalışmalar Clostridium difficile enfeksiyonuna karşı tedavi geliştirmek için yapılmıştır. Günümüzde mikrobiyotanın daha iyi tanınması ile gastrointestinal sistem dışında birçok mekanizmayı etkilediği belirlenmiştir. Mikrobiyotadaki olumsuzlukların çeşitli hastalıklara neden olduğu belirlenmiş ve yeni tedavi statejileri geliştirilmeye çalışılmaktadır. Bunlar arasında son dönemlerde fekal mikrobiyota transplantasyonuna (FMT) dikkat çekmektedir. FMT, çeşitli ülkelerde popüler olarak uygulanmakta ve umut vaat etmektedir. Ancak uygulama sonrası uzun dönem takibin olmaması FMT konusunda eleştirilere yol açmıştır ve uygulamanın güvenilirliği konusunda daha çok çalışmaya ihtiyaç duyulmaktadır.

🔖

Cite This Article

AKYÜZ, E. Y., SÜRÜCÜ, Y. (2020). Fecal microbiota transplantation and its effects on diseases. Sağlık Akademisyenleri Dergisi, Cilt: 7 - Sayı: 4, 296–303. https://ajindex.com/articles/798335

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Heintz-Buschart, A., & Wilmes, P. (2018). Human Gut Microbiome: Function Matters. Trends in Microbiology, 26(7), 563–574
  2. Dominguez-Bello, M. G., Godoy-Vitorino, F., Knight, R., & Blaser, M. J. (2019). Role of the microbiome in human development. Gut, 68(6), 1108-1114
  3. Human Microbiome Project, C., 2012. Structure, function and diversity of the healthy human microbiome. Nature. 486, 207-214
  4. Holmes, A., Finger, C., Morales-Scheihing, D., Lee, J., & McCullough, L. D. (2020). GUT DYSBIOSIS AND AGE-RELATED NEUROLOGICAL DISEASES; AN INNOVATIVE APPROACH FOR THERAPEUTIC INTERVENTIONS. Translational Research
  5. Pflughoeft, K. J., & Versalovic, J. (2012). Human Microbiome in Health and Disease. Annual Review of Pathology: Mechanisms of Disease, 7, 99-122
  6. Neish, A. S. (2009). Microbes in Gastrointestinal Health and Disease. Gastroenterology, 136(1), 65-80
  7. Durack, J., & Lynch, S. V. (2019). The gut microbiome: Relationships with disease and opportunities for therapy. Journal of Experimental Medicine, 216(1), 20-40
  8. Lu, C. C., Ma, K. L., Ruan, X. Z., & Liu, B. C. (2018). Intestinal dysbiosis activates renal renin-angiotensin system contributing to incipient diabetic nephropathy. International journal of medical sciences, 15(8), 816
  9. Brandt, L. J., & Aroniadis, O. C. (2013). An overview of fecal microbiota transplantation: Techniques, indications, and outcomes. Gastrointestinal endoscopy, 78(2), 240-249
  10. Stebel, R., Vojtilova, L., Svacinka, R., & Husa, P. (2020). Faecal microbiota transplantation in the treatment of Clostridioides difficile infection. Human Microbiome Journal, 100070
  11. Kim, K. O., & Gluck, M. (2019). Fecal Microbiota Transplantation: An Update on Clinical Practice. Clinical endoscopy, 52(2), 137
  12. Van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M.,. & Speelman, P. (2013). Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. New England Journal of Medicine, 368(5), 407-415
  13. Weingarden, A. R., & Vaughn, B. P. (2017). Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut microbes, 8(3), 238-252
  14. Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A.,. & Gordon, J. I. (2004). The gut microbiota as an environmental factor that regulates fat storage. Proceedings of the national academy of sciences, 101(44), 15718-15723
  15. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gord